ABSINasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Absci Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$8.54+0.29 (+3.52%)

Close on Oct 19, 2026

Market cap: $1.34B
P/E (TTM): –
Dividend yield: –

Dividends

Absci has not reported a dividend

No dividend per share appears in Absci's annual filings since fiscal 2019.

Where these numbers come from

Parsed from the XBRL in Absci's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ABSI.

Revenue growth-62.3% · median 21.9%

Operating margin-8084.5% · median -452.8%

Net margin-7756.4% · median -420.8%

Company	Revenue	Growth
OABI	$38.46M	+67.0%
BIAF	$5.90M	-23.2%
ABSI	$1.56M	-62.3%
ONMD	$1.46M	+216.5%
ISPC	$466.30K	-92.1%
AIDX	–	–

Company

Next earnings (est.): Nov 11, 2026, after close
Exchange: Nasdaq
Industry: Services-Commercial Physical & Biological Research
Fiscal year ends: December 31
Employees: 140
Held by institutions: 88.3%
Auditor: Ernst & Young LLP
SEC CIK: 1672688

Advertisement
300 × 250